Related Experiment Videos
Pharmacokinetics of cefotaxime in neonates
Insights
Gestational age does not significantly alter cefotaxime pharmacokinetics in newborns. A 50 mg/kg dose every 12 hours is appropriate for infants under seven days old, considering their longer drug elimination half-life.
Area of Science:
- Neonatal Pharmacology
- Pediatric Pharmacokinetics
- Antibiotic Drug Metabolism
Background:
- Cefotaxime is a crucial antibiotic for neonatal infections.
- Understanding its pharmacokinetics in neonates is vital for safe and effective dosing.
- Gestational age and factors like betamethasone may influence drug metabolism.
Purpose of the Study:
- To investigate the impact of gestational age on cefotaxime pharmacokinetics in neonates.
- To assess the influence of betamethasone on cefotaxime metabolism.
- To determine appropriate cefotaxime dosing for early neonatal life.
Main Methods:
- Pharmacokinetic analysis of cefotaxime and its metabolite in full-term and preterm infants.
- Comparison between preterm infants with and without betamethasone exposure.
- Measurement of cefotaxime elimination half-life (T 1/2 beta) and metabolite presence.
Main Results:
- No significant pharmacokinetic differences in cefotaxime were found across gestational age groups or with betamethasone exposure.
- Cefotaxime elimination half-life ranged from 4.04 to 4.56 hours.
- The desacetyl metabolite was consistently present, unaffected by betamethasone.
Conclusions:
- Neonatal cefotaxime elimination half-life is longer than in older populations, likely due to reduced renal excretion.
- Gestational age and betamethasone do not significantly impact cefotaxime pharmacokinetics in the early neonatal period.
- A cefotaxime dose of 50 mg/kg every 12 hours is recommended for infants less than seven days old.
Abstract:
The effects of gestational age on the pharmacokinetics of cefotaxime and its desacetyl metabolite during the first days of life was investigated in a group of four full-term infants and 12 preterm infants of less than 35 weeks gestation. Half of the preterm infants had received betamethasone, a drug known to facilitate hepatic microsomal drug metabolism, whilst the others had not. No significant differences in the pharmacokinetics of cefotaxime were observed between the various groups, with elimination half-life (T 1/2 beta) of cefotaxime ranging from 4.04 +/- 1.52 to 4.56 +/- 1.31 h. The desacetyl metabolite of cefotaxime was present in all post-dose serum samples, irrespective of the gestational age of the baby. Its formation was apparently unaffected by prior exposure to betamethasone. The elimination half-life of cefotaxime is significantly longer in newborn infants than in older children or adults, this increase probably results from decreased renal excretion of the drug, rather than from immaturity in its metabolism. A dose of 50 mg/kg of cefotaxime given every 12 h is appropriate for infants of less than seven days old.